** Shares of medical device maker Tivic Health Systems TIVC.O more than double to 49 cents; set to record the largest single-day percentage gain
** TIVC says it has acquired exclusive worldwide rights from Statera Biopharma STAB.PK to a late-stage immunotherapy drug called entolimod, which is used for the treatment of acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation
** The deal includes an initial payment of $1.2 million in equity and $300,000 in cash to Statera
** Drug has the potential to be approved by the U.S. FDA within two years - TIVC
** The FDA has granted "fast track" and "orphan drug" designation to entolimod for the treatment of ARS - TIVC
** The global ARS market is estimated to be valued at $5.2 billion in 2024 with a compound annual growth rate of 5% from 2024 to 2031 - TIVC
** TIVC fell 80.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。